INCY$116.71

Incyte shows solid top-line momentum, with revenue rising from $3.0B in FY2021 to $5.1B in FY2025 and TTM reaching $5.4B, indicating continued acceleration. Profitability is strong at the gross level, with gross margin staying consistently above 92%, but operating margin has been volatile: it compressed sharply in FY2024 on a surge in R&D, then rebounded to about 29-30% in FY2025 and TTM. Net income is less consistent because of unusual swings in other income/expense and taxes, including a very low FY2024 result and a large FY2021 tax benefit. Overall, earnings power appears durable, but the recent volatility and expense sensitivity keep the profile below top-tier.

Incyte’s balance sheet looks very solid, with strong liquidity and conservative leverage. FY2025 cash and short-term investments rose to $3.58 billion, or $4.02 billion on a TTM basis, versus current liabilities of $1.52 billion, leaving ample working capital. Total current assets increased to $5.02 billion and total assets to $6.96 billion, comfortably exceeding total liabilities of $1.79 billion. Debt is minimal at about $34 million, so solvency risk appears low. Equity recovered sharply to $5.17 billion in FY2025 from $3.45 billion in FY2024, reflecting a normalized capital base after a temporary dip. The main flag is some volatility in cash and equity, but the overall structure remains strong and resilient.

Cash generation is solid but uneven. Operating cash flow rose from $749.5 million in FY2021 to $969.9 million in FY2022, then fell to $496.5 million in FY2023 and $335.3 million in FY2024 before rebounding sharply to $1.414 billion in FY2025 and $1.517 billion TTM. Free cash flow followed the same pattern, recovering to $1.355 billion in FY2025 after a weak $249.1 million in FY2024, with a strong 26.4% FCF margin TTM. CapEx remains modest, so reinvestment is controlled. Working capital swings are material, especially receivables, inventories, and accrued expenses. Capital allocation was mixed, with a very large FY2024 buyback and then lower repurchases afterward.

Liquidity has been consistently strong, with the current ratio staying well above 3.0 in most years and the quick ratio similarly robust, aside from a temporary dip in FY2024. That suggests short-term obligations are comfortably covered. Leverage is very light, with debt-to-equity near zero throughout and net debt remaining negative, indicating a net cash position and low balance-sheet risk. Efficiency is mixed but acceptable: asset turnover improved overall, while inventory turnover has trended lower recently, pointing to somewhat weaker inventory use. Profitability is solid, though not perfectly smooth, with ROE, ROA, ROIC and ROCE falling sharply in FY2024 before rebounding strongly in FY2025 and holding up in the current period.

Incyte’s top line shows a clear growth runway, with revenue rising from the low-3s to over 6 by FY2027 and forecast growth staying near 9% after a stronger FY2025–FY2026 pace. That suggests a transition from faster expansion into steadier compounding rather than a sharp slowdown. EPS has been much more volatile than revenue, with a weak FY2024 followed by a strong rebound and then continued forecast gains, implying improving earnings power and potentially better margins. The forward P/E falls from 19.61 to 13.83 as growth accelerates, which looks broadly consistent with the outlook. Analyst sentiment is constructive, with a Buy consensus from 26 analysts, a wide but positive target range, and a recommendation mix that has remained fairly stable over recent months.